Inman Pharmacy owner Mike Reppucci says reimbursements on GLP-1s often come in below the cost to acquire the drugs. (Nicole DeFeudis for Endpoints News)
October 31, 2023 10:30 AM EDTUpdated 03:22 PM
Health Tech

Lo­cal phar­ma­cies say they're strug­gling to af­ford GLP-1s

Nicole DeFeudis

Editor

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)

Har­ry Webb has seen a flur­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times